Detalhe da pesquisa
1.
Creating Virtual Models and 3D Movies Using DemoMaker for Anatomical Education.
Adv Exp Med Biol
; 1431: 161-175, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37644292
2.
Defective Monocyte Enzymatic Function and an Inhibitory Immune Phenotype in Human Immunodeficiency Virus-Exposed Uninfected African Infants in the Era of Antiretroviral Therapy.
J Infect Dis
; 226(7): 1243-1255, 2022 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403683
3.
Early T Cell Differentiation with Well-Maintained Function across the Adult Life Course in Sub-Saharan Africa.
J Immunol
; 203(5): 1160-1171, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31358657
4.
Spontaneous Flares of Chronic Hepatitis B Virus in Hepatitis Be Antigen Negative Carriers Who Subsequently Clear Hepatitis B Surface Antigen.
Dig Dis Sci
; 66(1): 257-262, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32034604
5.
How fast should social restrictions be eased in England as COVID-19 vaccinations are rolled out?
Int J Clin Pract
; 75(7): e14191, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33788370
6.
"Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom.
Int J Clin Pract
; 75(3): e13674, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790942
7.
Assessing the spread of the novel coronavirus in the absence of mass testing.
Int J Clin Pract
; 75(4): e13836, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33258191
8.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171426
9.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178152
10.
Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.
Radiology
; 297(3): 622-629, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33078998
11.
The effects of hyperthermia on human hepatocellular carcinoma stem and mature cancer cells.
Ann Hepatol
; 19(3): 265-268, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32005636
12.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29621991
13.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(6): 732-742, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526536
14.
Trastuzumab-associated cardiac events in the Persephone trial.
Br J Cancer
; 115(12): 1462-1470, 2016 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27875516
15.
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Lancet
; 395(10223): 492-493, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32061290
16.
Essential role of eIF5-mimic protein in animal development is linked to control of ATF4 expression.
Nucleic Acids Res
; 42(16): 10321-30, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25147208
17.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med
; 367(19): 1783-91, 2012 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23020162
18.
Is undertransfusion a problem in modern clinical practice?
Transfusion
; 55(4): 906-10, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25331063
19.
Implementation of a clinical decision support system improves compliance with restrictive transfusion policies in hematology patients.
Transfusion
; 55(8): 1964-71, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25906831
20.
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Cancer
; 120(5): 642-51, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24222194